2022 ASTRO-Myovant Sciences-Pfizer Alliance New Combination (Relugolix-Radiation) Therapy Challenge
View the Challenge Program Announcement (PA) for detailed instructions.
Please visit the Pfizer ISR Grant System to submit your research proposal.
All entries are due by 11:59 p.m. Eastern time (GMT -5) on July 18, 2022.
Frequently Asked Questions (FAQ) are available for access and review.
Purpose
To catalyze new collaborative research opportunities, and to facilitate radiation oncology leadership in scientific discovery with the Myovant Sciences-Pfizer Alliance in the space of multimodality combination therapy.
Challenge Statement/Research Areas of Interest
How can prostate cancer treatment be improved with the gonadotropin-releasing hormone (GnRH) receptor antagonist relugolix in patients receiving radiotherapy?
Research proposals in the following topic areas are encouraged:
- Use of relugolix with definitive radiotherapy (concomitant/adjuvant/neoadjuvant) in prostate cancer patients with high/very high risk, unfavorable intermediate risk and regional disease
- Use of relugolix with radiotherapy as salvage therapy post treatment with curative intent
- Concomitant treatment with other oral oncolytics (e.g., ARIs)
- Synchronous oligometastatic/metastatic and oligoprogressive disease
Studies of interest may include evaluating the following:
- Clinical outcomes (i.e., rPFS, MFS, local control, etc.)
- Testosterone kinetics
- Patient-Reported Outcomes (PROs)
- Safety/Adverse Events (AEs)
- Compliance/adherence
- Translational research such as exploratory biomarkers and mechanistic studies may be considered as part of a clinical trial
Topic areas out-of-scope include:
- Recurrent oligometastatic disease
- Retrospective studies
- All other tumor sites
- Ex-U.S. studies
Geographic Scope
United States
Budget
The target budget for each individual project grant is up to U.S. $500,000 (Total costs, which include both direct and indirect costs). However, individual projects requesting higher amounts will be considered based on scientific merit and funding availability. Overhead (indirect cost) rates of up to 28% of the total proposed project budget are allowed.
The amount of the Myovant Sciences-Pfizer Alliance funds for any project will depend upon the expert review panel’s (ERP) (also known as the Challenge Judging Panel) evaluation of the proposal and costs involved and will be stated clearly in the approval notification.
Funding for the 2022 ASTRO-Myovant Sciences-Pfizer New Combination Therapy Challenge is up to $2,500,000, across three to five projects.
Number of Grants
Up to three to five awards as selected by the expert review panel
Entry Due Date
July 18, 2022; 11:59 p.m. Eastern time (GMT -5)
Grantor
Myovant Sciences-Pfizer Alliance
Grant Agreement Requirements
If your entry is recommended by the ASTRO Challenge Judging Panel, your institution will be required to enter into a written grant agreement with Pfizer and Myovant in order that support can be provided. View the core terms of the agreement (though note that this is not the complete contract template). Neither Pfizer nor Myovant have the resources to negotiate grant agreements, so please ensure that your institution is able and willing to abide by these terms before proceeding with your application.
Program Contact
Visit www.pfizer.com/ISR to sign up for alerts and/or email questions about this PA to the ASTRO Department of Scientific Affairs.
